Aloxiprin (or aluminium acetylsalicylate) is a medical drug used for the treatment of pain and inflammation associated with muscular skeletal and joint disorders. It is used for its properties as an anti-inflammatory, antipyretic and analgesic drug.[1] It is a chemical compound of aluminium hydroxide and aspirin.[2][3]

Aloxiprin
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • aluminium 2-acetyloxybenzoate hydroxide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.041.481 Edit this at Wikidata
Chemical and physical data
FormulaC18H15AlO9
Molar mass402.291 g·mol−1
3D model (JSmol)
  • [Al+3].O=C(Oc1ccccc1C([O-])=O)C.[OH-].[O-]C(=O)c1ccccc1OC(=O)C

  • CC(=O)Oc0ccccc0C(=O)O[Al](O)OC(=O)c1ccccc1OC(=O)C
  • InChI=1S/2C9H8O4.Al.H2O/c2*1-6(10)13-8-5-3-2-4-7(8)9(11)12;;/h2*2-5H,1H3,(H,11,12);;1H2/q;;+3;/p-3 checkY
  • Key:MANKSFVECICGLK-UHFFFAOYSA-K checkY
  (verify)

Alternative names and combinations

edit

Contraindications

edit
  • People with allergies to salicylates.
  • People with gastrointestinal ulcers.
  • People with liver or kidney damage.
  • Pregnant women in the 3rd trimester.
  • Women who are breastfeeding.
  • Use with other salicylates.
  • Use with NSAIDs.

References

edit
  1. ^ MIMS. "Aloxiprin". MIMS. Retrieved 16 April 2011.
  2. ^ Encarta. "Aloxiprin". Encarta. Retrieved 16 April 2011.[permanent dead link]
  3. ^ CUMMINGS AJ, MARTIN BK, WIGGINS LF (1963). "In vitro and in vivo properties of aloxiprin: a new aluminium derivative of acetylsalicylic acid". J. Pharm. Pharmacol. 15: 56–62. doi:10.1111/j.2042-7158.1963.tb12743.x. PMID 14024235. S2CID 33366977.
  4. ^ Geller J (1968). "A comparative trial of aloxiprin ('Palaprin Forte') and phenylbutazone ('Butazolidin')". The British Journal of Clinical Practice. 22 (9): 392–4. PMID 4876729.
  5. ^ Net Doctor UK. "Askit Powders". Treatments for joint, muscle and bone conditions. Retrieved 16 April 2011.
edit